DALLAS, July 18, 2016 -- Greater fluctuations in "bad" cholesterol levels may be linked to worse cognitive function in elderly adults, according to new research in the American Heart Association's journal Circulation.
In a study of European adults age 70 to 82 years old, researchers found that greater fluctuations in low-density lipoprotein cholesterol (LDL), or "bad" cholesterol, are associated with lower cognitive performance.
For example, study participants with the highest LDL cholesterol variability took 2.7 seconds longer on average to finish a cognitive test to name ink colors of color words written in different ink (for example, the word blue written in red ink), compared to individuals with the lowest variability.
"While this might seem like a small effect, it is significant at a population level," said Roelof Smit, M.D., lead study author and a Ph.D. student at Leiden University Medical Center in Leiden, the Netherlands.
The link between variability and declining cognitive function was found regardless of average bad cholesterol levels or use of cholesterol-lowering statin drugs.
In addition, greater fluctuations in bad cholesterol were associated with lower brain blood flow and greater white matter hyperintensity load - which has been linked to endothelial dysfunction.
These results show LDL cholesterol variability may be important to neurocognitive function, Smit said.
"Our findings suggest for the first time that it's not just the average level of your LDL-cholesterol that is related to brain health, but also how much your levels vary from one measurement to another," Smit said.
Measurements fluctuate because of diet, exercise, frequency of cholesterol-lowering statins and other factors, he said. However, these fluctuations might also reflect an increasingly impaired homeostasis; for example, due to age or underlying disease, added J.Wouter Jukema, M.D., Ph.D., senior author of the study and professor of Cardiology at the Leiden University Medical Center.
The research involved 4,428 participants from Scotland, Ireland and the Netherlands in the PROspective Study of Pravastatin in the Elderly at Risk. PROSPER participants either had preexisting vascular disease or were at a higher risk for developing the condition because of histories of hypertension, cigarette smoking or diabetes.
Researchers examined associations between LDL cholesterol variability and four cognitive measures: color-word test for selective attention, letter-digit coding to assess information processing speed and picture-word learning to test verbal memory in two ways - immediate recall and delayed recall after 20 minutes.
Although the research population was European, the results may be applicable to Americans as their lifestyle patterns predispose them to the same set of clinical outcomes, Smit said. But the results cannot be extrapolated directly to the general U.S. population because the study participants were older adults at high risk for vascular disease.
"These results add an important puzzle piece to the emerging evidence that vascular risk factors are closely related to brain health," Smit said. "Our study is just the first exciting step. Further studies are needed to examine whether these findings could truly influence clinical practice."
Co-authors are Stella Trompet, Ph.D.; Behnam Sabayan, M.D., Ph.D.; Saskia le Cessie, Ph.D.; Jeroen van der Grond, Ph.D.; Mark van Buchem, M.D., Ph.D.; Anton de Craen, Ph.D.; and J. Wouter Jukema, M.D., Ph.D. Author disclosures are on the manuscript.
Bristol-Myers Squibb funded the study.
Brain health infographic and cholesterol test images are located in the right column of this release link http://newsroom.
After July 18, view the manuscript online.
Protect Your Heart, Protect Your Brain
Cognitive Challenges After Stroke
Don't Regret Your Brain Health
Follow AHA/ASA news on Twitter @HeartNews.
For updates and new science from the Circulation journal follow @CircAHA.
Subscribe to the Circulation on the Run iTunes podcast - a weekly overview of the issue's contents for the busy clinician.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.